Amarin Corporation: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
Amarin Corporation is | [[File:Amarin_Corporation_logo.svg|thumb]]<br>Amarin Corporation | ||
Amarin Corporation is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. The company is best known for its prescription drug, [[Vascepa]], which is derived from fish oil and is used to reduce cardiovascular risk. | |||
{{ | |||
==History== | |||
Amarin Corporation was founded in 1993 and is headquartered in [[Dublin]], [[Ireland]]. Initially, the company focused on the development of lipid science and the treatment of cardiovascular disease. Over the years, Amarin has shifted its focus to the commercialization of its flagship product, Vascepa. | |||
==Products== | |||
===Vascepa=== | |||
Vascepa is Amarin's primary product, an omega-3 fatty acid-based drug designed to lower triglyceride levels in patients with severe hypertriglyceridemia. It has been approved by the [[Food and Drug Administration]] (FDA) for use in the United States and has undergone various clinical trials to expand its indications. | |||
==Research and Development== | |||
Amarin Corporation invests heavily in research and development to explore new therapeutic uses for Vascepa and other potential products. The company conducts clinical trials to assess the efficacy and safety of its products in reducing cardiovascular events. | |||
==Market and Sales== | |||
Amarin markets Vascepa primarily in the United States, with efforts to expand its presence in international markets. The company employs a direct sales force and partners with other pharmaceutical companies to promote its products. | |||
==Legal and Regulatory Affairs== | |||
Amarin has been involved in various legal and regulatory matters, including patent disputes and challenges related to the marketing and labeling of Vascepa. The company actively engages with regulatory bodies to ensure compliance and to seek approval for expanded indications of its products. | |||
==Corporate Structure== | |||
Amarin Corporation is publicly traded on the [[NASDAQ]] stock exchange under the ticker symbol AMRN. The company is governed by a board of directors and managed by an executive team responsible for strategic decisions and day-to-day operations. | |||
==Related pages== | |||
* [[Biopharmaceutical company]] | |||
* [[Cardiovascular disease]] | |||
* [[Omega-3 fatty acid]] | |||
* [[Hypertriglyceridemia]] | |||
{{Amarin Corporation}} | |||
[[Category:Biopharmaceutical companies]] | |||
[[Category:Companies established in 1993]] | |||
[[Category:Companies based in Dublin]] | |||
Latest revision as of 04:25, 9 January 2025
Amarin Corporation
Amarin Corporation is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. The company is best known for its prescription drug, Vascepa, which is derived from fish oil and is used to reduce cardiovascular risk.
History[edit]
Amarin Corporation was founded in 1993 and is headquartered in Dublin, Ireland. Initially, the company focused on the development of lipid science and the treatment of cardiovascular disease. Over the years, Amarin has shifted its focus to the commercialization of its flagship product, Vascepa.
Products[edit]
Vascepa[edit]
Vascepa is Amarin's primary product, an omega-3 fatty acid-based drug designed to lower triglyceride levels in patients with severe hypertriglyceridemia. It has been approved by the Food and Drug Administration (FDA) for use in the United States and has undergone various clinical trials to expand its indications.
Research and Development[edit]
Amarin Corporation invests heavily in research and development to explore new therapeutic uses for Vascepa and other potential products. The company conducts clinical trials to assess the efficacy and safety of its products in reducing cardiovascular events.
Market and Sales[edit]
Amarin markets Vascepa primarily in the United States, with efforts to expand its presence in international markets. The company employs a direct sales force and partners with other pharmaceutical companies to promote its products.
Legal and Regulatory Affairs[edit]
Amarin has been involved in various legal and regulatory matters, including patent disputes and challenges related to the marketing and labeling of Vascepa. The company actively engages with regulatory bodies to ensure compliance and to seek approval for expanded indications of its products.
Corporate Structure[edit]
Amarin Corporation is publicly traded on the NASDAQ stock exchange under the ticker symbol AMRN. The company is governed by a board of directors and managed by an executive team responsible for strategic decisions and day-to-day operations.
